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Abstract The SLC10 family of sodium/bile salt cotrans-
porters contains over 50 members in animal, plant and
bacterial species. In man, two well-characterized mem-
bers and three orphan transporters are known. The
Na+/taurocholate cotransporting polypeptide (NTCP;
SLC10A1) and the apical sodium-dependent bile salt
transporter (ASBT; SLC10A2) are critical components of
the enterohepatic circulation of bile salts. NTCP and
ASBT are cotransporters that mediate sodium-dependent,
electrogenic uptake of mainly bile salts into hepatocytes
(NTCP), biliary epithelial cells, ileal enterocytes and
renal proximal tubular cells (ASBT).
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Introduction
Bile formation is essential for normal intestinal lipid
digestion and absorption, cholesterol homeostasis, and for
the hepatic excretion of lipid-soluble xenobiotics, drugs,
and heavy metals. Bile secreted by the liver is composed
mainly of bile salts (~67%), phospholipids, cholesterol
and proteins. After their secretion, bile salts travel down
the biliary tree and are stored in the gallbladder. In
response to a meal the gallbladder empties its contents
into the duodenum where the bile salts play an essential
role in the efficient digestion and absorption of lipids and
lipid soluble vitamins (i.e. vitamins A, D, E and K). In the
terminal ileum bile salts are absorbed almost quantita-
tively and return to the liver with the portal circulation.
The small amount of fecal bile salt loss (~5% of the total)
is balanced by hepatic conversion of cholesterol to bile
salts, a process representing an important route for
elimination of cholesterol from the body. In the liver,
bile salts are removed actively from portal blood and re-
secreted into bile (Fig. 1). Because this continuous flow of
bile salts is restricted to the hepatocytes, the biliary tree,
the intestine, and the portal blood, the system is called the
enterohepatic circulation. This enterohepatic circulation is
dependent on several transport systems, among which the
two sodium-dependent bile salt cotransporters of the
SLC10 family play a crucial role. The Na+/taurocholate
cotransporting polypeptide (NTCP; SLC10A1) located at
the sinusoidal plasma membrane of hepatocytes (Fig. 1)
extracts bile salts efficiently from portal blood for re-
secretion across the canalicular membrane into the bile. In
parallel, the apical sodium-dependent bile salt transporter
(ASBT; SLC10A2), expressed at the brush border mem-
brane of ileocytes (Fig. 1), actively removes bile salts
from the intestinal lumen and allows their return to the
liver via the portal circulation. Most of the bile salts
secreted by hepatocytes are not newly synthesized and
have undergone enterohepatic recycling. As such, distur-
bances in bile salt synthesis, biliary secretion, and
enterohepatic cycling all have profound effects on hepatic
and gastrointestinal physiology.
Brief history
The rat Ntcp (Slc10a1) was isolated by expression cloning
using the Xenopus laevis oocyte system [1]. This cDNA
was used subsequently to identify a human NTCP
ortholog [2]. Two splice variants have been isolated
subsequently from mouse liver [3]. Expression cloning
was also employed to isolate the ASBT from a hamster
ileal cDNA library [4]. This resulted in the subsequent
identification of the rat [5], human [6], rabbit [7], and
mouse [8] ASBT orthologs (Table 1).
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Functional characteristics
Both NTCP and the ASBT have been expressed in
different recombinant systems including Xenopus laevis
oocytes [1], COS-7 [9], CHO [10], HPCT-1E3 [11],
MDCK [12, 13], HEK 293 [14], and rat hepatoma cells
[15]. Both transport systems mediate Na+-dependent
uptake of conjugated and unconjugated bile salts and
the only non-bile salt substrate identified so far for NTCP
is estrone-3-sulfate [10]. The driving force for NTCP- and
ASBT-mediated bile salt uptake is provided by the
inwardly directed Na+ gradient maintained by the baso-
lateral Na+, K+-ATPase as well as the negative intracel-
lular potential. Detailed analysis has revealed that
transport is electrogenic with a sodium:taurocholate
stoichiometry of at least 2:1 [16, 17]. Very recent studies
of ASBT chimeras have shown that the benzothiazepine-
based inhibitors interact with specific residues in the
carboxyl-terminal transmembrane domain [18]. These
data, as well as previous chemical modification experi-
ments, indicate strongly that the two C-terminal putative
transmembrane domains constitute an important part of
the binding pocket for bile salts [14]. The importance of
the C-terminal part of NTCP and ASBT is supported by
the recent demonstration that the glutamic acid at position
257 as well as the cysteine at position 266 in rat Ntcp
(both completely conserved among eight members of the
Fig. 1 Cellular localization of
the SLC10 sodium bile salt
cotransporters Na+/taurocholate
cotransporting polypeptide
(NTCP) and the apical sodium-
dependent bile salt transporter
(ASBT). While expression of
NTCP is restricted to the sinu-
soidal membrane of hepa-
tocytes, ASBT has been
detected in the apical mem-
branes of ileal enterocytes
(ileocytes), of biliary endotheli-
al cells (cholangiocytes) and of
renal proximal tubular cells.
Secretion of bile salts across the
canalicular membrane of hepa-
tocytes is accomplished by the
ATP-dependent bile salt export
pump (BSEP), while the pro-
posed exchanger in the basolat-
eral membrane of ileocytes has
not yet been identified
Table 1 SLC10—the sodium bile salt cotransporter family
Human
gene
name
Protein
name
Aliases Predomi-
nant
substrates
Trans-
porter
type/
coupling
ions*
Tissue distribution
and cellular/
subcellular
expression
Link to
disease
(OMIM)
Human
gene
locus
Sequence
accession
ID
Splice variants
and their
specific
features
SLC10A1 NTCP LBAT Bile salts C/Na+ Liver, pancreas 14q24.1 NM_003049 Ntcp1/Ntcp2
(mouse)
SLC10A2 ASBT IBAT,
ISBT
Bile salts C/Na+ Ileum, kidney,
biliary tract
PBAM
(601295)
13q33 NM_000452 tASBT (rat)
SLC10A3 P3 O Ubiquitously (based
on EST data)
Xq28 NM_019848
SLC10A4 Hypotheti-
cal protein
MGC29802
O Brain neuroblastoma
(based on EST data)
4p11 NM_152679
SLC10A5 Similar to
P3 protein
O Fetal brain (based on
EST data)
8q21 XM_294493
*C Cotransporter, O orphan, EST expressed sequence tag
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SLC10 transporters) are essential for taurocholate trans-
port [19].
Computer programs have favored a seven-transmem-
brane domain topology for both NTCP and ASBT [2, 20].
However, recent experimental evidence based on trans-
lation/insertion scanning, alanine insertion and glycosy-
lation site mutagenesis suggest rather a nine-
transmembrane domain topology (Fig. 2) [21, 22].
Ultimately, an approach such as X-ray crystallography
will be required to determine the topology.
Individual members
SLC10A1
The human NTCP is a 349-amino acid polytopic mem-
brane glycoprotein with an apparent molecular mass of
approximately 56 kDa [2]. NTCP’s expression at the
basolateral (sinusoidal) membrane of human hepatocytes
and high affinity for conjugated bile salts (taurocholate
apparent Km ~6 M, taurochenodeoxycholate ~2 M)
promotes efficient extraction of bile salts from portal
blood to keep plasma concentrations at a minimum. In
addition to the liver, Ntcp is also expressed at the luminal
(apical) membrane of pancreatic acinar cells where it may
function to clear any bile salts that leak into the terminal
acini [23]. NTCP orthologs have been identified in the rat
[1] (362 amino acids, 77% amino acid identity to human
NTCP), and mouse [3]. In contrast to humans and rat, the
mouse Ntcp gene encodes two splice variants, Ntcp1 with
362 amino acids and the less-abundant Ntcp2 with 317
amino acids and a shorter C-terminal end [3].
NTCP’s properties satisfy all the functional criteria for
hepatocytic Na+-coupled bile salt uptake including: (a)
preferential high affinity transport of conjugated bile
salts, (b) kinetics for taurocholate transport similar to
isolated hepatocytes, (c) electrogenic Na+-taurocholate
uptake, (d) appropriate tissue-specific expression in the
liver, and (e) similar ontogeny for Na+-dependent bile salt
uptake and NTCP expression in development. The
overwhelming evidence indicates that NTCP accounts
for most, if not all, hepatic Na+-dependent bile salt
transport [24, 25]. NTCP mRNA and protein expression is
decreased in various animal models of cholestasis and
liver disease [26, 27]. In addition, recent studies have also
shown similar decreased NTCP expression in percutane-
ous liver biopsies of patients with cholestatic liver disease
[28]. An inherited defect in NTCP has not yet been
reported. It is possible that an isolated NTCP gene defect
is asymptomatic since the liver also expresses Na+-
independent bile salt transporters. However, a rare
disorder characterized by a relatively isolated hyper-
cholanemia has been described recently, and an NTCP
defect remains a candidate for at least a subset of those
patients [29].
SLC10A2
The human ASBT is a 348-amino acid polytopic mem-
brane glycoprotein with an apparent molecular mass of
approximately 50 kDa [20]. ASBT transports all major
species of bile salts, but favors trihydroxy (cholic acid,
CA) over dihydroxy bile salts, and conjugated over
unconjugated species. ASBT is expressed on the apical
brush border membrane at high levels in terminal ileum
and at lower levels in renal proximal tubules [30] and
biliary epithelium [31]. In the ileum and kidney, ASBT
functions as a salvage mechanism for efficient conserva-
tion of bile salts. In the bile ducts, ASBT’s function may
be to permit cholangiocytes to sample biliary contents to
activate cellular signaling pathways rather than to trans-
port significant quantities of bile salts [31]. ASBT shares
approximately 35% amino acid identity with NTCP, and
ASBT orthologs have been identified in the rat [5], mouse
[7], hamster [4] and rabbit [7]. Alternative splicing gives
rise to a novel truncated, 19-kDa form of ASBT in the rat.
A significant proportion of the ASBT transcript under-
goes exon-2 skipping, resulting in a frameshift at codon
126 and truncation of the ASBT protein from 348 to 154
amino acids. Preliminary evidence suggests that this
truncated protein (tASBT) functions on the basolateral
membrane as a bile salt efflux pump [32]. Notably, this is
the first example of a solute carrier gene encoding both
the solute uptake and efflux mechanisms.
The properties of ASBT satisfied all the functional
criteria for ileal active bile salt uptake including: (a) a
strict sodium dependence for bile salt transport, (b)
narrow substrate specificity encompassing only conjugat-
ed and unconjugated bile salts with negligible uptake of
other organic anions, (c) specific intestinal expression in
the terminal ileum, and (d) similar ontogeny for ileal
sodium-dependent taurocholate uptake and ASBT expres-
sion [33]. Finally, inherited mutations in the human
ASBT gene cause primary bile salt malabsorption, an
Fig. 2A, B Topological models of the SLC10 sodium bile salt
cotransporters. Computer modeling suggests seven transmembrane
(M) domains (A) while experimental evidence is compatible with a
nine-transmembrane domain model (B)
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idiopathic intestinal disorder associated with interruption
of the enterohepatic circulation of bile salts and fat
malabsorption [34]. This last finding demonstrates clearly
that most intestinal bile salt absorption in humans is
mediated by ASBT.
SLC10A3
P3 cDNA was originally cloned from placenta and
encodes a protein of 477 amino acids [35]. The function
of the P3 protein is currently unknown. However, on the
basis of its wide tissue expression and its conservation in
distant animal species, P3 protein is thought to encode a
protein with housekeeping functions. Since P3 shares
approximately 27% amino acid identity with the ASBT
and NTCP, it has been assigned to the “sodium/bile acid
symporter” family. However, to date there is no exper-
imental data indicating that the P3 protein functions in
solute transport and its function remains a mystery.
SLC10A4
This hypothetical protein MGC29802 of 437 amino acids
shares ~37% identity with human NTCP. The function of
MGC29802 is currently unknown. Based on expressed
sequence tag (EST) database searches, MGC29802
appears to be expressed predominantly in neuroblastomas.
However, its definitive tissue distribution as well as its
function will have to be determined experimentally.
SLC10A5
This is the third predicted orphan transporter and consists
of 297 amino acids and, based on EST data, is expressed
in the fetal brain.
SLC10 transporters as therapeutic targets
Inhibitors for treatment of hypercholesterolemia
and cholestasis
Inhibition of intestinal reabsorption of bile salts using
binding resins was an important early therapeutic strategy
for increasing hepatic cholesterol demand in order to
elevate low-density lipoprotein (LDL) receptor levels and
decrease plasma LDL. An alternative to luminal seques-
tration of bile salts by binding resins is to inhibit the
intestinal absorption of bile salts directly. As a result of its
intestinal expression and role in the enterohepatic circu-
lation, ASBT is a potential target for cholesterol-lowering
therapy and a variety of high-affinity inhibitors have been
developed. These inhibitors fall into two general classes,
bile salt-derivatives including bile salt dimers [36], and
non-bile salt compounds including benzothiazepine [37]
and benzothiepine analogs [38]. Two ileal bile salt
transporter inhibitors have entered phase-2 clinical trials
with an associated reduction in LDL cholesterol of 10%
reported in one trial [39].
SLC10 transporters as portals for drug delivery
With its restricted expression to hepatocytes NTCP is
ideally suited to target drugs to the liver. Thus, any kind
of liver-specific disease is a potential target for treatment
with drugs that are conjugated to bile salts, but which, in
an unconjugated form, do not home efficiently to the
liver. Possible examples are e.g. anti-viral drugs or pro-
drugs to treat hepatitis, hydroxymethylglutaryl-coenzyme
A (HMG-CoA) reductase inhibitors to lower cholesterol
levels or cytostatic drugs to treat hepatocellular carcino-
mas. The feasibility of such an approach has been shown
for several compounds such as e.g. antisense oligonucle-
otides, amino acids and peptides [40] as well as for
cytostatic drugs which keep their potency even after
conjugation to bile salts [41]. Similarly, oligopeptides
coupled to bile salts are readily absorbed in the small
intestine [42], which could be a useful way to improve the
bioavailability of orally applied peptide drugs.
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